Docetaxel and Nedaplatin Chemotherapy for Advanced Oral Squamous Cell Carcinoma : A Case Report

Abstract

A new chemotherapy regimen consisting of intravenous docetaxel (60 mg/m²) and nedaplatin (70 mg/m²) was performed in a 51-year-old patient with unresectable squamous cell carcinoma of the tongue (T4N0M0). After 2 courses of chemotherapy and follow-up irradiation, complete tumor regression was observed (clinical CR). Except for short-term grade 4 neutropenia and mucositis, severe toxicities were not observed. Excision of scar tissue at the tumor site was performed without causing tongue dysfunction, and pathological CR was confirmed. In the present case, DOC/CDGP chemotherapy followed by radiotherapy was effective against locally advanced squamous cell carcinoma of the tongue.